HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
In This Section
Garrett M. Brodeur, MD
Director, Cancer Predisposition Program
Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.
Bio
Dr. Broedur’s two principal research interests center on nanoparticle drug delivery and cancer predisposition. With respect to nanoparticle drug delivery, Dr. Broedur and his colleagues aim to develop more effective and less toxic therapy for pediatric cancers, especially solid tumors like neuroblastoma. Although agents targeting specific genes, proteins, and pathways are needed, targeted drug delivery could dramatically improve efficacy and decrease toxicity.
Dr. Brodeur also has research projects focused on identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals The ultimate aim of this research is to improve outcome and reduce side effects for patients.
Education and Training
BA, St. Louis University (Chemistry), 1971
MD, Washington University School of Medicine, 1975
Titles and Academic Titles
Director, Cancer Predisposition Program
Audrey E. Evans Endowed Chair in Pediatric Oncology
Attending Physician
Professor of Pediatrics
Professional Memberships
American Society of Hematology, 1980-
American Society of Clinical Oncology, 1980-
American Association for the Advancement of Science, 1983-
American Society of Pediatric Hematology-Oncology, 1983-
Society for Pediatric Research, 1985-
American Society for Clinical Investigation, 1990-
John Morgan Society, 1996-
Osler Interurban Clinical Club, 2001-
Association of American Physicians, 2015
Professional Awards
Faculty Mentor Award, Children's Hospital of Philadelphia, 2011
ASCO Pediatric Oncology Award, 2013
Lifetime Achievement Award, Advances in Neuroblastoma Research Association, 2014
Publication Highlights
PubMed:
Nguyen F, Alferiev I, Guan P, Guerrero DT, Kolla V, Moorthy GS, Chorny M, Brodeur GM. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model. Clin Cancer Res. 2018 Jun; 24(11):2585-2593 PMID: 29514842
Kamihara J, Bourdeaut F, Foulkes WD, Molenaar JJ, Mossé YP, Nakagawara A, Parareda A, Scollon SR, Schneider KW, Skalet AH, States LJ, Walsh MF, Diller LR, Brodeur GM. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 Jul; 23(13):e98-e106. Review. PMID: 28674118
Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D. Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. Clin Cancer Res. 2017 Jun; 23(11):e1-e5. Review. PMID: 28572261
Alferiev IS, Iyer R, Croucher JL, Adamo RF, Zhang K, Mangino JL, Kolla V, Fishbein I, Brodeur GM, Levy RJ, Chorny M. Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials. 2015 May; 51:22-29. PMID: 25770994
Iyer R, Croucher JL, Chorny M, Mangino JL, Alferiev IS, Levy RJ, Kolla V, Brodeur GM. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Lett. 2015 May; 360(2):205-12. PMID: 25684664
Links of Interest
Cancer Predisposition Program (Video)